Koru Medical price target raised to $3 from $2.50 at Piper Sandler

Piper Sandler analyst Jason Bednar raised the firm’s price target on Koru Medical to $3 from $2.50 and keeps an Overweight rating on the shares. The firm notes Koru Medical reported Q2 results, including revenue of $8.4M/+22% year-over-year that represents a record revenue quarter and easily beat the Street’s $7.6M with upside stemming from all reporting segments.